NCT04853927View on ClinicalTrials.gov

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 8, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19SARS (Severe Acute Respiratory Syndrome)
Interventions
DRUG

Proxalutamide

Proxalutamide 300mg q.d suspension

DRUG

Placebo

Proxalutamide 300mg q.d placebo

Trial Locations (1)

Unknown

Samel Hospital, Manaus

Sponsors
All Listed Sponsors
lead

Applied Biology, Inc.

INDUSTRY